Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Next generation of targeted dendritic cell vaccines for cancer treatment

Reference number
Coordinator 3H Biomedical AB
Funding from Vinnova SEK 500 000
Project duration October 2018 - March 2019
Status Completed

Purpose and goal

3H Biomedical has developed the next generation of targeted dendritic cell vaccines for cancer treatment.

Expected results and effects

We have built comprehensive experimental data, a vaccine development roadmap that contains a time based path through the entire development of the drug candidate from early stage pre-clinical studies to clinical trials.

Planned approach and implementation

1.We will improve and validate the production process of new drug candidates in human cells: DONE 2.We will study the functionality and effect of new drug candidates in preclinical experiments: DONE 3.Strengthen IP position: DONE 4.Seek collaboration with branch experts and pharma companies for drug development: DONE 5.Business plan consolidation to attract collaboration: DONE

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 24 October 2018

Reference number 2018-03109

Page statistics